Stock 4162 PHARMAENGINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PharmaEngine, Inc.

Equities

4162

TW0004162003

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
91.5 TWD +0.99% Intraday chart for PharmaEngine, Inc. +2.81% -13.27%
Apr. 24 PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors CI
Mar. 18 PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization 1 9,978 8,430 10,207 17,961 15,158 13,147
Enterprise Value (EV) 1 9,918 6,594 8,057 17,961 15,158 13,147
P/E ratio 236 x 14 x 24.7 x 56.3 x 55.2 x 49.5 x
Yield 0.73% 4.32% 3.72% 1.6% 1.42% 2.51%
Capitalization / Revenue 31.8 x 7.98 x 15.6 x 27.4 x 19.7 x 15.4 x
EV / Revenue 31.8 x 7.98 x 15.6 x 27.4 x 19.7 x 15.4 x
EV / EBITDA 253,787,890 x 10,252,261 x 27,368,850 x - - -
EV / FCF 628,744,706 x 130,155,710 x 10,982,158 x - - -
FCF Yield 0% 0% 0% - - -
Price to Book 2.86 x 2.12 x 2.67 x 4.64 x 3.92 x 3.39 x
Nbr of stocks (in thousands) 145,667 145,597 140,596 143,687 143,679 143,678
Reference price 2 68.50 57.90 72.60 125.0 105.5 91.50
Announcement Date 3/18/20 3/21/21 3/8/22 3/17/23 2/29/24 -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales 1 314 1,056 654.8 654.4 767.7 851
EBITDA 39.32 822.3 373 - - -
EBIT 1 32.61 809.7 362.7 282.7 277.2 239
Operating Margin 10.38% 76.68% 55.39% 43.21% 36.11% 28.08%
Earnings before Tax (EBT) 1 49.67 752.5 545.4 392.5 338 313
Net income 1 42.55 604.3 426 318.8 274.6 269
Net margin 13.55% 57.22% 65.06% 48.72% 35.78% 31.61%
EPS 2 0.2900 4.140 2.940 2.220 1.910 1.850
Free Cash Flow 15.87 64.77 929.4 - - -
FCF margin 5.05% 6.13% 141.94% - - -
FCF Conversion (EBITDA) 40.36% 7.88% 249.21% - - -
FCF Conversion (Net income) 37.3% 10.72% 218.16% - - -
Dividend per Share 2 0.5000 2.500 2.700 2.000 1.500 2.300
Announcement Date 3/18/20 3/21/21 3/8/22 3/17/23 2/29/24 -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 177.1 174.1 166.9 154.9 158.5 168.3 - 245.9 187.3 180 188 268 214
EBITDA - - - - - - - - - - - - -
EBIT 1 98.77 116.6 97.22 19.28 49.62 81.09 - 77.52 65.16 65 23 105 45
Operating Margin 55.76% 66.98% 58.25% 12.45% 31.31% 48.17% - 31.52% 34.79% 36.11% 12.23% 39.18% 21.03%
Earnings before Tax (EBT) 1 102.9 122.1 104.3 101.7 64.36 102.5 - 103.1 60.25 84 42 123 63
Net income 1 73.15 97.03 80.67 87.46 53.62 81.38 75.12 80.78 37.37 72 36 106 54
Net margin 41.3% 55.73% 48.33% 56.47% 33.83% 48.34% - 32.85% 19.95% 40% 19.15% 39.55% 25.23%
EPS 2 0.5100 0.6800 0.5600 0.6100 0.3700 0.5700 0.5200 0.5600 0.2600 0.4900 0.2500 0.7300 0.3700
Dividend per Share - - - - - - - - - - - - -
Announcement Date 11/10/21 5/6/22 8/3/22 11/4/22 3/17/23 5/4/23 8/4/23 11/6/23 2/29/24 - - - -
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt - - - - - -
Net Cash position 59.9 1,836 2,151 - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 15.9 64.8 929 - - -
ROE (net income / shareholders' equity) 1.19% 16.1% 10.7% - - -
ROA (Net income/ Total Assets) - 15.4% 10.3% - - -
Assets 1 - 3,925 4,117 - - -
Book Value Per Share 2 23.90 27.40 27.20 26.90 26.90 27.00
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 3/18/20 3/21/21 3/8/22 3/17/23 2/29/24 -
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
91.5
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PHARMAENGINE, INC. Stock PharmaEngine, Inc.
-13.27% 403M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 4162 Stock
  4. Financials PharmaEngine, Inc.